Published in Clin Infect Dis on May 15, 2010
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis (2014) 2.18
Respiratory cryptosporidiosis in HIV-seronegative children in Uganda: potential for respiratory transmission. Clin Infect Dis (2010) 1.56
Retention in care: a challenge to survival with HIV infection. Clin Infect Dis (2007) 10.66
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev (2002) 3.37
Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care (2005) 2.64
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.43
Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr (2003) 2.33
Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia (2014) 2.11
New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg (2005) 2.10
An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am (2006) 2.05
Neuroendoscopic diagnosis of central nervous system histoplasmosis with basilar arachnoiditis. World Neurosurg (2011) 2.05
Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis (2012) 1.95
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis (2005) 1.72
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev (2016) 1.66
A positive enzyme-linked immunoelectrotransfer blot assay result for a patient without evidence of cysticercosis. Clin Infect Dis (2002) 1.49
Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg (2009) 1.41
Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg (2005) 1.30
Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg (2010) 1.29
Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis (2010) 1.29
Zoonotic larval cestode infections: neglected, neglected tropical diseases? PLoS Negl Trop Dis (2009) 1.26
A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis (2013) 1.23
Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis (2009) 1.23
Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol (2007) 1.23
Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) (2011) 1.19
Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab (2002) 1.18
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis (2007) 1.17
Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis (2003) 1.12
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett (2012) 1.12
Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect (2007) 1.10
Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosis. AIDS (2002) 1.08
Cestode infestations: hydatid disease and cysticercosis. Infect Dis Clin North Am (2012) 1.05
Foxp3+ regulatory T cells in antiretroviral-naive HIV patients. AIDS (2006) 1.04
Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect (2008) 1.02
Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. Am J Trop Med Hyg (2003) 1.01
Enteropathogens and chronic illness in returning travelers. N Engl J Med (2013) 0.99
Interleukin-15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J Infect Dis (2005) 0.99
Neurocysticercosis in the United States. Pathog Glob Health (2012) 0.98
Cryptosporidium infection of human intestinal epithelial cells increases expression of osteoprotegerin: a novel mechanism for evasion of host defenses. J Infect Dis (2008) 0.94
Intestinal immune response to human Cryptosporidium sp. infection. Infect Immun (2007) 0.93
Human CD8(+) T cells clear Cryptosporidium parvum from infected intestinal epithelial cells. Am J Trop Med Hyg (2010) 0.92
Sequential expression of the neuropeptides substance P and somatostatin in granulomas associated with murine cysticercosis. Infect Immun (2002) 0.91
Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther (2006) 0.90
Seropositive human subjects produce interferon gamma after stimulation with recombinant Cryptosporidium hominis gp15. Am J Trop Med Hyg (2007) 0.90
Treatment of cryptosporidiosis. Expert Rev Anti Infect Ther (2009) 0.89
Burden of Fasciola hepatica Infection among children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg (2012) 0.88
Epileptogenic activity of granulomas associated with murine cysticercosis. Exp Neurol (2003) 0.88
Nitazoxanide: an important advance in anti-parasitic therapy. Am J Trop Med Hyg (2003) 0.88
Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection. Infect Immun (2013) 0.87
Workshop report: Developing an international collaborative research network in neurocysticercosis and epilepsy. Epilepsia (2009) 0.86
Cryopreservation modulates the detection of regulatory T cell markers. Cytometry B Clin Cytom (2011) 0.86
Neurocysticercosis in the HIV era: a case report and review of the literature. Am J Trop Med Hyg (2007) 0.85
New developments in epidemiology, diagnosis, and treatment of fascioliasis. Curr Opin Infect Dis (2012) 0.85
Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect (2004) 0.84
Characterization of excretory/secretory endopeptidase and metallo-aminopeptidases from Taenia crassiceps metacestodes. J Parasitol (2005) 0.84
Travelers' diarrhea: an update on susceptibility, prevention, and treatment. Curr Gastroenterol Rep (2008) 0.83
Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy. J Infect Dis (2010) 0.82
High levels of CXCL10 are produced by intestinal epithelial cells in AIDS patients with active cryptosporidiosis but not after reconstitution of immunity. Infect Immun (2006) 0.82
Substance P expression correlates with severity of diarrhea in cryptosporidiosis. J Infect Dis (2003) 0.81
Protection from murine cysticercosis by immunization with a parasite cysteine protease. Microbes Infect (2006) 0.80
Acute mountain sickness impact among travelers to Cusco, Peru. J Travel Med (2012) 0.79
Nitazoxanide for treatment of intestinal parasites in children. Pediatr Infect Dis J (2005) 0.79
Oligonucleotide-gold nanoparticle networks for detection of Cryptosporidium parvum heat shock protein 70 mRNA. J Clin Microbiol (2009) 0.79
Treatable bacterial infections are underrecognized causes of fever in Ethiopian children. Am J Trop Med Hyg (2012) 0.79
Symptoms of intestinal schistosomiasis presenting during treatment of large B cell lymphoma. Am J Trop Med Hyg (2004) 0.79
Proinflammatory cytokines in granulomas associated with murine cysticercosis are not the cause of seizures. J Parasitol (2006) 0.78
Management of potential neurocysticercosis in patients with HIV infection. Clin Infect Dis (2006) 0.78
Capillaria hepatica pseudoinfection. Am J Trop Med Hyg (2013) 0.77
Human studies provide insight into the pathogenesis, immunology, and treatment of cryptosporidiosis. Clin Infect Dis (2003) 0.77
Microsporidiasis. Handb Clin Neurol (2013) 0.76
Altered eosinophil proteome in a patient with hypereosinophilia from acute fascioliasis. Clin Vaccine Immunol (2011) 0.75
Hemorrhagic cerebrovascular events and neurocysticercosis: a case report and review of the literature. Am J Trop Med Hyg (2011) 0.75
CD4+ T cell subsets and Tax expression in HTLV-1 associated diseases. Pathog Glob Health (2013) 0.75
Cysteine proteinase inhibitors in murine cysticercosis. Antimicrob Agents Chemother (2006) 0.75
Why are there seizures in neurocysticercosis: is it in the genes? J Infect Dis (2010) 0.75
Treatment of chronic cryptosporidiosis in AIDS with rIL-12 induces an immune response associated with improvement but severe side-effects. AIDS (2005) 0.75
Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens. J Acquir Immune Defic Syndr (2003) 0.75
Unusual manifestations of disseminated Histoplasmosis in patients responding to antiretroviral therapy. Am J Med (2005) 0.75
We are (at risk with) what we eat. Curr Opin Infect Dis (2016) 0.75